Skip to main navigation
  • Contact Us linkedin
  • Homepage
  • About Us
    • Senior Leadership Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Approach
    • Our Platform
    • Publications & Presentations
  • Our Pipeline
    • Vilastobart (anti-CTLA-4)
    • Efarindodekin Alfa (IL-12)
    • XTX501
    • Masked T Cell Engagers
    • Expanded Access Policy
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports
    • Corporate Governance
      • Documents & Charters
      • Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Stock Information
      • Analyst Coverage
    • Investor FAQs
    • Email Alerts
    • Contact
  • Careers

Annual Reports

2024 Annual Report
2024 Annual Report 28.4 MB
2025 Proxy Statement 895.8 KB
2023 AR
2023 Annual Report 8.6 MB
2024 Proxy Statement 605.5 KB
2022AR
2022 Annual Report 31 MB
2023 Proxy Statement 516 KB
Xilio Therapeutics, Inc logo

Xilio Therapeutics
828 Winter Street, Waltham, MA 02451

© 2026 Xilio Therapeutics, Inc.
All Rights Reserved

Privacy Policy

We use cookies to help personalize your experience. For more information on how we use cookies and similar technologies, and how you can change your settings, please see our Privacy Policy.
Cookie SettingsOk